A Phase 1/2 interventional study of COR-001 and Placebo in Anemia, sponsored by Novo Nordisk A/S. Completed at 12 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-07-30.
Sponsored by Novo Nordisk A/S · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 464 studies in Anemia with a site in United States — 38 open to participants now, 58 under way, 18 of them phase 3. Anemia · United States.
Among the 464 studies in Anemia with a site in United States, this one is the 210th largest by enrollment of the 395 interventional ones that give a count, is one of 25 that started in 2016, is one of 19 in phase 1/2, and was the 305th registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →38 of the 464 studies in Anemia with a site in United States are open now. Recruiting first, the newest first:
John Mascarenhas · Sites in United States
Ages 18+
Takeda · Sites in United States, Argentina, Australia and 28 more countries
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Takeda · Sites in United States, Argentina, Australia and 25 more countries
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
464 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 71 · Phase 2 136 · Phase 3 122 · Phase 4 34
First in 1992; this study’s year is marked. 25 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 61 is below the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 72 across the 395 interventional studies, 116 across the 50 observational. Of the 367 that completed or were terminated, 196 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
231 of 464 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Novo Nordisk A/S has 4 studies filed under Anemia — fewer than ten, so there is no comparison to draw.
10 of the studies in Anemia with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06527391Phase 3University of MinnesotaCholine and Iron Deficiency | 2027-09-21 |
| NCT04747613Phase 3Novartis PharmaceuticalsLong-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria | 2027-10-18 |
| NCT06106269Mayo ClinicOutcomes and Quality of Life Following Rectal Artery Embolization for Bleeding Internal Hemorrhoids | 2026-12 |
| NCT05340465University of WashingtonDarbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants | 2027-01-30 |
| NCT06788691Weill Medical College of Cornell UniversityLuspatercept for Clonal Cytopenias of Uncertain Significance | 2027-02 |
Add all 10 to your calendar (.ics) → With an account.
Among the 464 studies in Anemia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, placebo-controlled trial designed to evaluate the safety, pharmacokinetics, and pharmacodynamic effects of multiple doses of COR-001 or placebo
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
EXCLUSION CRITERIA:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: COR-001
Other: Placebo
Characterization of Maximum Tolerated Dose (MTD)
The MTD assessment was based on safety data. If more than 2 of 8 active participants in a cohort experience a Dose-Limiting Toxicities (DLT), the MTD was considered to have been exceeded. The DLT threshold was defined using a threshold of greater than or equal to (\>=) Grade 3 events, which includes severe: infusion-related reactions, cardiopulmonary infusion reactions, anaphylaxis, or hypersensitivity. DLTs are defined as follows: 1. Confirmed Grade 3 neutropenia and representing a decline of \> 25% from baseline 2. Serious adverse events (SAEs) of infection in the presence of confirmed Grade 2 or higher new onset lymphopenia or new onset neutropenia. 3. ≥ Grade 3 ALT (Alanine transaminase) or AST(Aspartate transaminase) 4. ≥ Grade 4 hematologic toxicity 5. ≥ Grade 3 non-hematologic toxicity
Time frame: Weeks 0-24
Change in High-sensitivity C-reactive Protein (hsCRP): Week 4
Change from the baseline in hsCRP values to week 4 are presented.
Time frame: From baseline (mean of screening and day 1) to week 4
Change in Serum Amyloid A (SAA): Week 4
Change from the baseline in serum amyloid A (SAA) values to week 4 are presented.
Time frame: From baseline (mean of screening and day 1) to week 4
Number of Adverse Events of Special Interest
Frequency of events of interest by treatment group and dose from baseline until the end of the safety follow-up period (week 24) were reported. Adverse events of special interest included severe infusion-related reactions, hypersensitivity reaction during study drug infusion, anaphylaxis and neutropenia events of grade 2 or higher (i.e., absolute neutrophil count \<1500/mm\^3 and decline by at least 25% from baseline).
Time frame: Weeks 0-24
Number of Treatment Emergent Adverse Events (TEAEs)
An AE (adverse event) is any undesirable event or any untoward medical occurrence that occurs to a participant during the course of a study, or the protocol-defined time after study termination, whether or not that event is considered Study Drug-related. A TEAE was defined as an AE that initiated or worsened on or after the date of first dose of study drug up to the end of study. Number of TEAEs from baseline until the end of safety follow up (week 24) were presented.
Time frame: Week 0-24
Electrocardiogram (ECG)
A summary of the overall ECG interpretation and clinical significance from baseline until the end of the safety follow up period (week 24) is presented and categorized as Normal, Abnormal clinically significant (CS), Abnormal non clinically significant (NCS) and Missing.
Time frame: At baseline, week 6, week 12, week 18 and week 24
Number of Participants Who Developed Anti-drug Antibodies (ADAs)
Number of participants who developed ADAs from baseline until the end of the extended follow up period (week 35) were reported. Samples with detectable ADAs were classified as positive for ADAs. Samples without detectable ADAs were classified as negative for ADAs.
Time frame: Weeks 0-35
Number of Participants With ADA Titers
Number of participants with ADA titers for ADA-positive samples from baseline to week 35 is presented.
Time frame: Weeks 0-35
Number of Participants With Neutralizing ADAs
Number of participants with neutralizing ADAs from baseline to week 35 are presented.
Time frame: From baseline (mean of screening and week 1) to week 35
Change in Transferrin Saturation (TSAT): Week 4
Change from baseline in TSAT to week 4 is presented.
Time frame: From baseline (mean of screening and day 1) to week 4
Change in TSAT: Mean of Weeks 10-12
Change from baseline in TSAT to the mean of weeks 10-12 is presented.
Time frame: From baseline (mean of screening and day 1), week 10, week 12
Change in Reticulocyte Hemoglobin (CHr): Week 4
Change from baseline in CHr to week 4 is presented.
Time frame: From baseline (mean of screening and day 1) to week 4
Change in High Sensitivity C-reactive Protein (Hs-CRP): Mean of 10-12 Weeks
Change from baseline in hs-CRP to the mean of 10-12 weeks is presented.
Time frame: From baseline (mean of screening and day 1), week 10, week 12
Change in SAA: Mean of Weeks 10-12
Change from baseline in SAA to the mean of weeks 10-12 is presented.
Time frame: From baseline (mean of screening and day 1), week 10, week 12
Change in Serum Pre-albumin: Mean of 10-12 Weeks
Change from baseline in serum pre-albumin to the mean of 10-12 weeks is presented.
Time frame: From baseline (mean of screening and day 1), week 10, week 12
Change in Albumin: Week 12
Change from baseline in albumin to week 12 is presented.
Time frame: From baseline (mean of screening and day 1) to week 12
Change in Erythropoietin Resistance Index (ERI): Week 4
Change from baseline in ERI to week 4 is presented. ERI is defined as the epoetin alfa-equivalent dose (weight-based per week in U/kg) divided by the serum hemoglobin (in g/dL).
Time frame: From baseline (weekly mean of screening) to week 4
Change in ERI: Mean of Weeks 8-12
Change from baseline in ERI to the mean of weeks 8-12 is presented. ERI is defined as the epoetin alfa-equivalent dose (weight-based per week in U/kg) divided by the serum hemoglobin (in g/dL).
Time frame: From baseline (weekly mean of screening), week 8, week 12
Change in ERI: Mean of Weeks 10-12
Change from baseline in ERI to the mean of weeks 10-12 is presented. ERI is defined as the epoetin alfa-equivalent dose (weight-based per week in U/kg) divided by the serum hemoglobin (in g/dL).
Time frame: From baseline (weekly mean of screening), week 10, week 12
Change in CHr: Mean of Weeks 10-12
Change from baseline in CHr to the mean of weeks 10-12 is presented.
Time frame: From baseline (mean of screening and day 1), week 10, week 12
Change in Hemoglobin: Week 4
Change from baseline in hemoglobin to week 4 is presented.
Time frame: From baseline (mean of screening and day 1) to week 4
Change in Hemoglobin: Mean of Weeks 10-12
Change from baseline in hemoglobin to weeks 10-12 is presented.
Time frame: From baseline (mean of screening and day 1), week 10, week 12
Change in Hemoglobin: Mean of Weeks 10-12, Excluding Hemoglobin Values Following a Change in the Total Weekly ESA Dose
Change from baseline in hemoglobin to weeks 10-12, excluding hemoglobin values following a change in the total weekly ESA (erythropoiesis stimulating agent) dose is presented. A change is defined as the first time when the ESA weekly dose goes up by \>25% or down by \>25% relative to the previous week's dose.
Time frame: From baseline (mean of screening and day 1), week 10, week 12
Change in ERI: Week 12
Change from baseline in ERI to week 12 is presented. ERI is defined as the epoetin alfa-equivalent dose (weight-based per week in U/kg) divided by the serum hemoglobin (in g/dL).
Time frame: From baseline (weekly mean of screening) to week 12
Change in ERI: Mean of Weeks 9-12
Change from baseline in ERI to the mean of weeks 9-12 is presented. ERI is defined as the epoetin alfa-equivalent dose (weight-based per week in U/kg) divided by the serum hemoglobin (in g/dL).
Time frame: From baseline (weekly mean of screening), week 9, week 12
Change in Hemoglobin: Week 12
Change from baseline in hemoglobin to week 12 is presented.
Time frame: From baseline (mean of screening and day 1) to week 12
Change in Hemoglobin: Week 24
Change from baseline in hemoglobin to week 24 is presented.
Time frame: From baseline (mean of screening and day 1) to week 24
Change in Hemoglobin From Screening to Peak Hemoglobin: Week 4
Change in hemoglobin from screening to peak hemoglobin at week 4 is presented.
Time frame: From screening to week 4
Basophils: Week 12
The observed values of basophils at week 12 are presented.
Time frame: At week 12
Basophil: Week 24
The observed values of basophils at week 24 are presented.
Time frame: At week 24
Basophils to Leukocytes Ratio: Week 12
Basophils to leukocytes ratio at week 12 is presented.
Time frame: At week 12
Basophils to Leukocytes Ratio: Week 24
Basophils to leukocytes ratio at week 24 is presented.
Time frame: At week 24
Eosinophils: Week 12
The observed values of eosinophils at week 12 are presented.
Time frame: At week 12
Eosinophils: Week 24
The observed values of eosinophils at week 24 are presented.
Time frame: At week 24
Eosinophils to Leukocytes Ratio: Week 12
Eosinophils to leukocytes ratio at week 12 is presented.
Time frame: At week 12
Eosinophils to Leukocytes Ratio: Week 24
The eosinophils to leukocytes ratio at week 24 is presented.
Time frame: At week 24
Erythrocyte Mean Corpuscular Hemoglobin: Week 12
The observed values of erythrocyte mean corpuscular hemoglobin at week 12 are presented.
Time frame: At week 12
Erythrocyte Mean Corpuscular Hemoglobin: Week 24
The observed values of erythrocyte mean corpuscular hemoglobin at week 24 are presented.
Time frame: At week 24
Erythrocyte Mean Corpuscular Hemoglobin (HGB) Concentration: Week 12
The observed values of erythrocyte mean corpuscular HGB concentration at week 12 are presented.
Time frame: At week 12
Erythrocyte Mean Corpuscular HGB Concentration: Week 24
The observed values of erythrocyte mean corpuscular HGB concentration at week 24 are presented.
Time frame: At week 24
Erythrocyte Mean Corpuscular Volume: Week 12
The observed values of erythrocyte mean corpuscular volume at week 12 are presented.
Time frame: At week 12
Erythrocyte Mean Corpuscular Volume: Week 24
The observed values of erythrocyte mean corpuscular volume at week 24 are presented.
Time frame: At week 24
Erythrocytes: Week 12
The observed values of erythrocytes at week 12 are presented.
Time frame: At week 12
Erythrocytes: Week 24
The observed values of erythrocytes at week 24 are presented.
Time frame: At week 24
Hematocrit: Week 12
The observed values of hematocrit at week 12 are presented.
Time frame: At week 12
Hematocrit: Week 24
The observed values of hematocrit at week 24 are presented.
Time frame: At week 24
Hemoglobin: Week 12
The observed values of hemoglobin at week 12 are presented.
Time frame: At week 12
Hemoglobin: Week 24
The observed values of hemoglobin at week 24 are presented.
Time frame: At week 24
Hypochromatic Red Cells Week 12
The observed values of hypochromatic red cells at week 12 are presented.
Time frame: At week 12
Hypochromatic Red Cells: Week 24
The observed values of hypochromatic red cells at week 24 are presented.
Time frame: At week 24
Leukocytes: Week 12
The observed values of leukocytes at week 12 are presented.
Time frame: At week 12
Leukocytes: Week 24
The observed values of leukocytes at week 24 are presented.
Time frame: At week 24
Lymphocytes: Week 12
The observed values of lymphocytes at week 12 are presented.
Time frame: At week 12
Lymphocytes: Week 24
The observed values of lymphocytes at week 24 are presented.
Time frame: At week 24
Lymphocytes to Leukocytes Ratio: Week 12
Lymphocytes to leukocytes ratio at week 12 is presented.
Time frame: At week 12
Lymphocytes to Leukocytes Ratio at Week 24
Lymphocytes to leukocytes ratio at week 24 is presented.
Time frame: At week 24
Monocytes: Week 12
The observed values of monocytes at week 12 are presented.
Time frame: At week 12
Monocytes: Week 24
The observed values of monocytes at week 24 are presented.
Time frame: At week 24
Monocytes to Leukocytes Ratio: Week 12
Monocytes to leukocytes ratio at week 12 is presented.
Time frame: At week 12
Monocytes to Leukocytes Ratio: Week 24
Monocytes to leukocytes ratio at week 24 is presented.
Time frame: At week 24
Neutrophils: Week 12
The observed values of neutrophils at week 12 are presented.
Time frame: At week 12
Neutrophils: Week 24
The observed values of neutrophils at week 24 are presented.
Time frame: At week 24
Neutrophils to Leukocytes Ratio: Week 12
Neutrophils to leukocytes ratio at week 12 is presented.
Time frame: At week 12
Neutrophils to Leukocytes Ratio: Week 24
Neutrophils to leukocytes ratio at week 24 is presented.
Time frame: At week 24
Platelets: Week 12
The observed values of platelets at week 12 are presented.
Time frame: At week 12
Platelets: Week 24
The observed values of platelets at week 24 are presented.
Time frame: At week 24
Reticulocytes to Erythrocytes Ratio: Week 12
Reticulocytes to erythrocytes ratio at week 12 is presented.
Time frame: At week 12
Reticulocytes to Erythrocytes Ratio: Week 24
Reticulocytes to erythrocytes ratio at week 24 is presented.
Time frame: At week 24
Alanine Aminotransferase: Week 12
The observed values of alanine aminotransferase at week 12 are presented.
Time frame: At week 12
Alanine Aminotransferase: Week 24
The observed values of alanine aminotransferase at week 24 are presented.
Time frame: At week 24
Albumin: Week 12
The observed values of albumin at week 12 are presented.
Time frame: At week 12
Albumin: Week 24
The observed values of albumin at week 24 are presented.
Time frame: At week 24
Alkaline Phosphatase: Week 12
The observed values of alkaline phosphatase at week 12 are presented.
Time frame: At week 12
Alkaline Phosphatase: Week 24
The observed values of alkaline phosphatase at week 24 are presented.
Time frame: At week 24
Aspartate Aminotransferase: Week 12
The observed values of aspartate aminotransferase at week 12 are presented.
Time frame: At week 12
Aspartate Aminotransferase: Week 24
The observed values of aspartate aminotransferase at week 24 are presented.
Time frame: At week 24
Bicarbonate: Week 12
The observed values of bicarbonate at week 12 are presented.
Time frame: At week 12
Bicarbonate: Week 24
The observed values of bicarbonate at week 24 are presented.
Time frame: At week 24
Bilirubin: Week 12
The observed values of bilirubin at week 12 are presented.
Time frame: At week 12
Bilirubin: Week 24
The observed values of bilirubin at week 24 are presented.
Time frame: At week 24
Calcium: Week 12
The observed values of calcium at week 12 are presented.
Time frame: At week 12
Calcium: Week 24
The observed values of calcium at week 24 are presented.
Time frame: At week 24
Chloride: Week 12
The observed values of chloride at week 12 are presented.
Time frame: At week 12
Chloride: Week 24
The observed values of chloride at week 24 are presented.
Time frame: At week 24
Cholesterol: Week 12
The observed values of cholesterol at week 12 are presented.
Time frame: At week 12
Cholesterol: Week 24
The observed values of cholesterol at week 24 are presented.
Time frame: At week 24
Creatinine: Week 12
The observed values of creatinine at week 12 are presented.
Time frame: At week 12
Creatinine: Week 24
The observed values of creatinine at week 24 are presented.
Time frame: At week 24
Direct Bilirubin: Week 12
The observed values of direct bilirubin at week 12 are presented.
Time frame: At week 12
Direct Bilirubin: Week 24
The observed values of direct bilirubin at week 24 are presented.
Time frame: At week 24
Glucose: Week 12
The observed values of glucose at week 12 are presented.
Time frame: At week 12
Glucose: Week 24
The observed values of glucose at week 24 are presented.
Time frame: At week 24
High-density Lipoprotein (HDL) Cholesterol: Week 12
The observed values of HDL cholesterol at week 12 are presented.
Time frame: At week 12
HDL Cholesterol: Week 24
The observed values of HDL cholesterol at week 24 are presented.
Time frame: At week 24
Hepcidin-25: Week 12
The observed values of hepcidin-25 at week 12 are presented.
Time frame: At week 12
Hepcidin-25: Week 24
The observed values of hepcidin-25 at week 24 are presented.
Time frame: At week 24
Low-density Lipoproteins (LDL) Cholesterol: Week 12
The observed values of LDL cholesterol at week 12 are presented.
Time frame: At week 12
LDL Cholesterol: Week 24
The observed values of LDL cholesterol at week 24 are presented.
Time frame: At week 24
Lipoprotein-a: Week 12
The observed values of lipoprotein-a at week 12 are presented.
Time frame: At week 12
Lipoprotein-a: Week 24
The observed values of lipoprotein-a at week 24 are presented.
Time frame: At week 24
Phosphate: Week 12
The observed values of phosphate at week 12 are presented.
Time frame: At week 12
Phosphate: Week 24
The observed values of phosphate at week 24 are presented.
Time frame: At week 24
Potassium: Week 12
The observed values of potassium at week 12 are presented.
Time frame: At week 12
Potassium: Week 24
The observed values of potassium at week 24 are presented.
Time frame: At week 24
Sodium: Week 12
The observed values of sodium at week 12 are presented.
Time frame: At week 12
Sodium: Week 24
The observed values of sodium at week 24 are presented.
Time frame: At week 24
Triglycerides: Week 12
The observed values of triglyceride at week 12 are presented.
Time frame: At week 12
Triglycerides: Week 24
The observed values of triglycerides at week 24 are presented.
Time frame: At week 24
Urea Nitrogen: Week 12
The observed values of urea nitrogen at week 12 are presented.
Time frame: At week 12
Urea Nitrogen: Week 24
The observed values of urea nitrogen at week 24 are presented.
Time frame: At week 24
Pre-dialysis Body Mass Index (BMI): Week 12
Pre-dialysis BMI values at week 12 are presented.
Time frame: At week 12
Pre-infusion BMI: Week 11
Pre-infusion BMI values at week 11 are presented.
Time frame: At week 11
Pre-dialysis Diastolic Blood Pressure: Week 12
Pre-dialysis diastolic blood pressure values at week 12 are presented.
Time frame: At week 12
Pre-dialysis Diastolic Blood Pressure: Week 24
Pre-dialysis diastolic blood pressure values at week 24 are presented.
Time frame: At week 24
Pre-infusion Diastolic Blood Pressure: Week 11
Pre-infusion diastolic blood pressure values at week 11 are presented.
Time frame: At week 11
Pre-dialysis Heart Rate: Week 12
Pre-dialysis heart rate values at week 12 are presented.
Time frame: At week 12
Pre-dialysis Heart Rate: Week 24
Pre-dialysis heart rate values at week 24 are presented.
Time frame: At week 24
Pre-infusion Heart Rate: Week 11
Pre-infusion heart rate values at week 11 are presented.
Time frame: At week 11
Pre-dialysis Respiration Rate: Week 12
Pre-dialysis respiration rate values at week 12 are presented.
Time frame: At week 12
Pre-dialysis Respiration Rate: Week 24
Pre-dialysis respiration rate values at week 24 are presented.
Time frame: At week 24
Pre-infusion Respiration Rate: Week 11
Pre-infusion respiration rate values at week 11 are presented.
Time frame: At week 11
Pre-dialysis Systolic Blood Pressure: Week 12
Pre-dialysis values of systolic blood pressure at week 12 are presented.
Time frame: At week 12
Pre-dialysis Systolic Blood Pressure: Week 24
Pre-dialysis values of systolic blood pressure at week 24 are presented.
Time frame: At week 24
Pre-infusion Systolic Blood Pressure: Week 11
Pre-infusion systolic blood pressure values at week 11 are presented.
Time frame: At week 11
Pre-dialysis Weight: Week 12
Pre-dialysis weight values at week 12 are presented.
Time frame: At week 12
Pre-infusion Weight: Week 11
Pre-infusion weight values at week 11 are presented.
Time frame: At week 11
Pre-dialysis Temperature: Week 12
Pre-dialysis temperature values at week 12 are presented.
Time frame: At week 12
Pre-dialysis Temperature: Week 24
Pre-dialysis temperature values at week 24 are presented.
Time frame: At week 24
Pre-infusion Temperature: Week 11
Pre-infusion temperature values at week 11 are presented.
Time frame: At week 11
Area Under the Serum Concentration Time Curve From Time 0 to Infinity (AUC 0-α) of COR-001
Area under the serum concentration time curve from time 0 to infinity (AUC 0-α) of COR-001 is presented.
Time frame: Week 1 (day 1, 3, and 5), Week 2 (day 8), Week 3 (day 15), Week 5 (day 29), Week 7 (day 43), Week 8 (day 50), Week 9 (day 57), Week 11 (day 71 and 75), Week 14 (day 92), Week 18 (day 120) and Week 35 (day 239).
Elimination Half-life in the Initial Phase (t 1/2,α)
Elimination half-life in the initial phase (t 1/2,α) is presented from week 0 to week 35.
Time frame: Week 1 (day 1, 3, and 5), Week 2 (day 8), Week 3 (day 15), Week 5 (day 29), Week 7 (day 43), Week 8 (day 50), Week 9 (day 57), Week 11 (day 71 and 75), Week 14 (day 92), Week 18 (day 120) and Week 35 (day 239).
Elimination Half-life in the Terminal Phase (t 1/2, z)
Elimination half-life in the terminal phase(t 1/2, z) is presented from week 0 to week 35.
Time frame: Week 1 (day 1, 3, and 5), Week 2 (day 8), Week 3 (day 15), Week 5 (day 29), Week 7 (day 43), Week 8 (day 50), Week 9 (day 57), Week 11 (day 71 and 75), Week 14 (day 92), Week 18 (day 120) and Week 35 (day 239).
Maximum Serum Concentration (Cmax)
Maximum serum concentration (Cmax) of COR-001 from week 0 to week 35 is presented.
Time frame: Week 1 (day 1, 3, and 5), Week 2 (day 8), Week 3 (day 15), Week 5 (day 29), Week 7 (day 43), Week 8 (day 50), Week 9 (day 57), Week 11 (day 71 and 75), Week 14 (day 92), Week 18 (day 120) and Week 35 (day 239).
Impact of ADAs on Pharmacokinetics
Presence of ADA was a covariate for pharmacokinetics (PK) affecting V1 (volume of distribution for the central compartment). Impact of ADAs on V1 from baseline to week 35 is presented. In the below table, result presented is the bootstrap parameter estimate of the effect of ADA on V1 for a PK model that includes data for all arms combined.
Time frame: Week 1 (day 1, 3, and 5), Week 2 (day 8), Week 3 (day 15), Week 5 (day 29), Week 7 (day 43), Week 8 (day 50), Week 9 (day 57), Week 11 (day 71 and 75), Week 14 (day 92), Week 18 (day 120) and Week 35 (day 239).
The trial was conducted at 13 sites in the United States.
| Milestone | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Started | 12 | 16 | 16 | 17 |
| Intent to treat (itt) population | 12 | 16 | 16 | 17 |
| Pharmacodynamic (pd) population | 12 | 16 | 13 | 12 |
| Pharmacokinetic (pk) population | 12 | 16 | 16 | 17 |
| Safety analysis population | 12 | 16 | 16 | 17 |
| Maximum tolerated dose (mtd) population | 12 | 16 | 16 | 16 |
| Completed | 11 | 16 | 15 | 12 |
| Not completed | 1 | 0 | 1 | 5 |
| Withdrew: Adverse event | 1 | 0 | 0 | 1 |
| Withdrew: Death | 0 | 0 | 1 | 1 |
| Withdrew: Missed dose | 0 | 0 | 0 | 3 |
The MTD assessment was based on safety data. If more than 2 of 8 active participants in a cohort experience a Dose-Limiting Toxicities (DLT), the MTD was considered to have been exceeded. The DLT threshold was defined using a threshold of greater than or equal to (\>=) Grade 3 events, which includes severe: infusion-related reactions, cardiopulmonary infusion reactions, anaphylaxis, or hypersensitivity. DLTs are defined as follows: 1. Confirmed Grade 3 neutropenia and representing a decline of \> 25% from baseline 2. Serious adverse events (SAEs) of infection in the presence of confirmed Grade 2 or higher new onset lymphopenia or new onset neutropenia. 3. ≥ Grade 3 ALT (Alanine transaminase) or AST(Aspartate transaminase) 4. ≥ Grade 4 hematologic toxicity 5. ≥ Grade 3 non-hematologic toxicity
| Events | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Infection SAEs with confirmed Grade 2 or higher new onset lymphopenia or new onset neutropenia. | 0 | 0 | 0 | 0 |
| >= Grade 3 ALT or AST | 0 | 0 | 0 | 0 |
| >= Grade 4 hematologic toxicity | 0 | 0 | 0 | 0 |
| >= Grade 3 non-hematologic toxicity | 0 | 0 | 0 | 0 |
| Confirmed Grade 3 neutropenia and representing a decline of > 25% from baseline | 0 | 0 | 0 | 0 |
Change from the baseline in hsCRP values to week 4 are presented.
| Milligrams per liter (mg/L) | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Change in High-sensitivity C-reactive Protein (hsCRP): Week 4 | 0.373 ± 3.765 | -10.383 ± 10.395 | -11.981 ± 8.232 | -14.561 ± 11.836 |
Change from the baseline in serum amyloid A (SAA) values to week 4 are presented.
| mg/L | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Change in Serum Amyloid A (SAA): Week 4 | -3.733 ± 6.955 | -22.056 ± 37.914 | -9.878 ± 6.687 | -31.910 ± 41.502 |
Frequency of events of interest by treatment group and dose from baseline until the end of the safety follow-up period (week 24) were reported. Adverse events of special interest included severe infusion-related reactions, hypersensitivity reaction during study drug infusion, anaphylaxis and neutropenia events of grade 2 or higher (i.e., absolute neutrophil count \<1500/mm\^3 and decline by at least 25% from baseline).
| Events | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Number of Adverse Events of Special Interest | 0 | 0 | 0 | 0 |
An AE (adverse event) is any undesirable event or any untoward medical occurrence that occurs to a participant during the course of a study, or the protocol-defined time after study termination, whether or not that event is considered Study Drug-related. A TEAE was defined as an AE that initiated or worsened on or after the date of first dose of study drug up to the end of study. Number of TEAEs from baseline until the end of safety follow up (week 24) were presented.
| Events | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Number of Treatment Emergent Adverse Events (TEAEs) | 33 | 51 | 83 | 66 |
A summary of the overall ECG interpretation and clinical significance from baseline until the end of the safety follow up period (week 24) is presented and categorized as Normal, Abnormal clinically significant (CS), Abnormal non clinically significant (NCS) and Missing.
| Participants | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Baseline — Normal | 5 | 7 | 4 | 7 |
| Baseline — Abnormal, clinically significant (CS) | 1 | 1 | 1 | 1 |
| Baseline — Abnormal, non clinically significant (NCS) | 6 | 8 | 11 | 9 |
| Baseline — Missing | 0 | 0 | 0 | 0 |
| Week 6 — Normal | 6 | 3 | 4 | 4 |
| Week 6 — Abnormal, clinically significant (CS) | 1 | 1 | 1 | 0 |
| Week 6 — Abnormal, non clinically significant (NCS) | 5 | 12 | 8 | 10 |
| Week 6 — Missing | 0 | 0 | 3 | 3 |
| Week 12 — Normal | 4 | 5 | 3 | 3 |
| Week 12 — Abnormal, clinically significant (CS) | 1 | 1 | 2 | 1 |
| Week 12 — Abnormal, non clinically significant (NCS) | 7 | 10 | 10 | 11 |
| Week 12 — Missing | 0 | 0 | 1 | 2 |
| Week 18 — Normal | 7 | 4 | 4 | 2 |
| Week 18 — Abnormal, clinically significant (CS) | 1 | 1 | 0 | 0 |
| Week 18 — Abnormal, non clinically significant (NCS) | 4 | 11 | 8 | 9 |
| Week 18 — Missing | 0 | 0 | 4 | 6 |
| Week 24 — Normal | 3 | 5 | 5 | 0 |
| Week 24 — Abnormal, clinically significant (CS) | 1 | 1 | 0 | 1 |
| Week 24 — Abnormal, non clinically significant (NCS) | 7 | 10 | 8 | 10 |
| Week 24 — Missing | 1 | 0 | 3 | 6 |
Number of participants who developed ADAs from baseline until the end of the extended follow up period (week 35) were reported. Samples with detectable ADAs were classified as positive for ADAs. Samples without detectable ADAs were classified as negative for ADAs.
| Participants | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Positive | 2 | 2 | 1 | 4 |
| Negative | 10 | 14 | 15 | 13 |
Number of participants with ADA titers for ADA-positive samples from baseline to week 35 is presented.
| Participants | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Number of Participants With ADA Titers | 2 | 2 | 1 | 4 |
Number of participants with neutralizing ADAs from baseline to week 35 are presented.
| Participants | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Number of Participants With Neutralizing ADAs | 0 | 0 | 0 | 0 |
Change from baseline in TSAT to week 4 is presented.
| Percentage of TSAT | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Change in Transferrin Saturation (TSAT): Week 4 | 0.467 ± 6.733 | 5.622 ± 12.942 | 1.806 ± 11.197 | 15.778 ± 12.384 |
Change from baseline in TSAT to the mean of weeks 10-12 is presented.
| Percentage of TSAT | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Change in TSAT: Mean of Weeks 10-12 | 2.278 ± 8.093 | 6.417 ± 7.157 | 9.167 ± 8.569 | 9.028 ± 6.121 |
Change from baseline in CHr to week 4 is presented.
| Picograms (pg) | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Change in Reticulocyte Hemoglobin (CHr): Week 4 | -0.265 ± 1.216 | 1.197 ± 1.183 | 1.188 ± 1.090 | 0.286 ± 2.265 |
Change from baseline in hs-CRP to the mean of 10-12 weeks is presented.
| mg/L | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Change in High Sensitivity C-reactive Protein (Hs-CRP): Mean of 10-12 Weeks | -0.021 ± 0.293 | -0.534 ± 0.439 | -0.916 ± 0.337 | -1.462 ± 0.554 |
Change from baseline in SAA to the mean of weeks 10-12 is presented.
| mg/L | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Change in SAA: Mean of Weeks 10-12 | -1.262 ± 19.056 | -24.323 ± 41.375 | -8.688 ± 6.665 | -30.324 ± 37.812 |
Change from baseline in serum pre-albumin to the mean of 10-12 weeks is presented.
| Milligrams per decilitre (mg/dL) | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Change in Serum Pre-albumin: Mean of 10-12 Weeks | 0.273 ± 5.716 | 6.032 ± 6.989 | 8.571 ± 5.362 | 11.170 ± 4.983 |
Change from baseline in albumin to week 12 is presented.
| Grams per decilitre (g/dL) | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Change in Albumin: Week 12 | 0.042 ± 0.288 | 0.122 ± 0.212 | 0.192 ± 0.151 | 0.336 ± 0.192 |
Change from baseline in ERI to week 4 is presented. ERI is defined as the epoetin alfa-equivalent dose (weight-based per week in U/kg) divided by the serum hemoglobin (in g/dL).
| (Unit/kg/week) per (g/dL) | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Change in Erythropoietin Resistance Index (ERI): Week 4 | -1.444 ± 3.590 | -0.975 ± 1.716 | -3.175 ± 4.761 | -4.211 ± 5.785 |
Change from baseline in ERI to the mean of weeks 8-12 is presented. ERI is defined as the epoetin alfa-equivalent dose (weight-based per week in U/kg) divided by the serum hemoglobin (in g/dL).
| (Units/kg/week) per (g/dL) | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Change in ERI: Mean of Weeks 8-12 | -2.714 ± 10.546 | -5.689 ± 7.824 | -7.842 ± 8.231 | -8.787 ± 5.952 |
Change from baseline in ERI to the mean of weeks 10-12 is presented. ERI is defined as the epoetin alfa-equivalent dose (weight-based per week in U/kg) divided by the serum hemoglobin (in g/dL).
| (Units/kg/week) per (g/dL) | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Change in ERI: Mean of Weeks 10-12 | -2.112 ± 11.476 | -6.477 ± 8.756 | -8.272 ± 8.770 | -8.690 ± 6.005 |
Change from baseline in CHr to the mean of weeks 10-12 is presented.
| pg | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Change in CHr: Mean of Weeks 10-12 | -0.035 ± 1.264 | 0.859 ± 1.098 | 1.271 ± 1.264 | 1.143 ± 1.635 |
Change from baseline in hemoglobin to week 4 is presented.
| g/dL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Change in Hemoglobin: Week 4 | -0.043 ± 1.416 | 0.473 ± 0.751 | 0.805 ± 0.957 | 0.973 ± 0.720 |
Change from baseline in hemoglobin to weeks 10-12 is presented.
| g/dL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Change in Hemoglobin: Mean of Weeks 10-12 | -0.107 ± 1.756 | 0.848 ± 1.156 | 0.963 ± 1.131 | 0.772 ± 1.236 |
Change from baseline in hemoglobin to weeks 10-12, excluding hemoglobin values following a change in the total weekly ESA (erythropoiesis stimulating agent) dose is presented. A change is defined as the first time when the ESA weekly dose goes up by \>25% or down by \>25% relative to the previous week's dose.
| g/dL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Change in Hemoglobin: Mean of Weeks 10-12, Excluding Hemoglobin Values Following a Change in the Total Weekly ESA Dose | 0.352 ± 1.225 | 0.228 ± 0.506 | 0.627 ± 0.988 | 0.567 ± 1.226 |
Change from baseline in ERI to week 12 is presented. ERI is defined as the epoetin alfa-equivalent dose (weight-based per week in U/kg) divided by the serum hemoglobin (in g/dL).
| (Units/kg/week) per (g/dL) | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Change in ERI: Week 12 | -3.229 ± 12.084 | -6.381 ± 8.956 | -8.835 ± 8.785 | -8.690 ± 6.356 |
Change from baseline in ERI to the mean of weeks 9-12 is presented. ERI is defined as the epoetin alfa-equivalent dose (weight-based per week in U/kg) divided by the serum hemoglobin (in g/dL).
| (Units/kg/week) per (g/dL) | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Change in ERI: Mean of Weeks 9-12 | -2.320 ± 11.392 | -6.338 ± 8.870 | -8.293 ± 8.780 | -8.756 ± 5.949 |
Change from baseline in hemoglobin to week 12 is presented.
| g/dL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Change in Hemoglobin: Week 12 | 0.130 ± 1.240 | 0.502 ± 1.029 | 0.806 ± 1.234 | 0.755 ± 1.379 |
Change from baseline in hemoglobin to week 24 is presented.
| g/dL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Change in Hemoglobin: Week 24 | -0.803 ± 1.929 | 0.154 ± 1.083 | -0.267 ± 0.826 | -0.079 ± 0.703 |
Change in hemoglobin from screening to peak hemoglobin at week 4 is presented.
| g/dL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Change in Hemoglobin From Screening to Peak Hemoglobin: Week 4 | -0.043 ± 1.416 | 0.473 ± 0.751 | 0.805 ± 0.957 | 0.973 ± 0.720 |
The observed values of basophils at week 12 are presented.
| 10^3 cells per microliter(10^3 cells/uL) | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Basophils: Week 12 | 0.03 ± 0.048 | 0.02 ± 0.041 | 0.04 ± 0.051 | 0.03 ± 0.062 |
The observed values of basophils at week 24 are presented.
| 10^3 cells/uL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Basophil: Week 24 | 0.05 ± 0.052 | 0.04 ± 0.062 | 0.08 ± 0.083 | 0.02 ± 0.042 |
Basophils to leukocytes ratio at week 12 is presented.
| Ratio of basophils to leukocytes | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Basophils to Leukocytes Ratio: Week 12 | 0.65 ± 0.458 | 0.45 ± 0.553 | 0.95 ± 0.447 | 0.87 ± 0.954 |
Basophils to leukocytes ratio at week 24 is presented.
| Ratio of basophils to leukocytes | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Basophils to Leukocytes Ratio: Week 24 | 0.62 ± 0.458 | 0.83 ± 0.722 | 1.29 ± 1.296 | 0.57 ± 0.521 |
The observed values of eosinophils at week 12 are presented.
| 10^3 cells/uL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Eosinophils: Week 12 | 0.16 ± 0.070 | 0.35 ± 0.247 | 0.18 ± 0.080 | 0.65 ± 1.706 |
The observed values of eosinophils at week 24 are presented.
| 10^3 cells/uL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Eosinophils: Week 24 | 0.19 ± 0.083 | 0.29 ± 0.189 | 0.30 ± 0.336 | 0.36 ± 0.683 |
Eosinophils to leukocytes ratio at week 12 is presented.
| Ratio of eosinophils to leukocytes | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Eosinophils to Leukocytes Ratio: Week 12 | 3.39 ± 1.433 | 5.56 ± 3.234 | 4.14 ± 1.669 | 7.32 ± 10.738 |
The eosinophils to leukocytes ratio at week 24 is presented.
| Ratio of eosinophils to leukocytes | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Eosinophils to Leukocytes Ratio: Week 24 | 3.49 ± 1.611 | 4.44 ± 2.287 | 5.32 ± 4.748 | 3.98 ± 3.985 |
The observed values of erythrocyte mean corpuscular hemoglobin at week 12 are presented.
| pg | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Erythrocyte Mean Corpuscular Hemoglobin: Week 12 | 30.2 ± 1.48 | 31.3 ± 2.66 | 30.8 ± 2.15 | 31.2 ± 2.48 |
The observed values of erythrocyte mean corpuscular hemoglobin at week 24 are presented.
| pg | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Erythrocyte Mean Corpuscular Hemoglobin: Week 24 | 29.5 ± 2.54 | 31.0 ± 2.80 | 30.6 ± 2.40 | 29.6 ± 2.46 |
The observed values of erythrocyte mean corpuscular HGB concentration at week 12 are presented.
| Grams per deciliter (g/dL) | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Erythrocyte Mean Corpuscular Hemoglobin (HGB) Concentration: Week 12 | 30.86 ± 1.332 | 31.41 ± 1.438 | 29.75 ± 1.563 | 31.23 ± 0.978 |
The observed values of erythrocyte mean corpuscular HGB concentration at week 24 are presented.
| g/dL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Erythrocyte Mean Corpuscular HGB Concentration: Week 24 | 30.78 ± 1.572 | 31.04 ± 1.307 | 29.52 ± 1.799 | 30.28 ± 1.297 |
The observed values of erythrocyte mean corpuscular volume at week 12 are presented.
| femtoliters (fL) | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Erythrocyte Mean Corpuscular Volume: Week 12 | 98.16 ± 4.328 | 99.35 ± 6.923 | 103.49 ± 9.153 | 99.97 ± 8.089 |
The observed values of erythrocyte mean corpuscular volume at week 24 are presented.
| fL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Erythrocyte Mean Corpuscular Volume: Week 24 | 95.70 ± 6.096 | 99.69 ± 6.859 | 103.53 ± 8.550 | 97.76 ± 6.983 |
The observed values of erythrocytes at week 12 are presented.
| 10^6 cells per microliter(10^6 cells/uL) | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Erythrocytes: Week 12 | 3.464 ± 0.302 | 3.348 ± 0.438 | 3.459 ± 0.411 | 3.370 ± 0.345 |
The observed values of erythrocytes at week 24 are presented.
| 10^6 cells/uL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Erythrocytes: Week 24 | 3.312 ± 0.480 | 3.256 ± 0.347 | 3.111 ± 0.388 | 3.365 ± 0.513 |
The observed values of hematocrit at week 12 are presented.
| Percentage of Hematocrit | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Hematocrit: Week 12 | 34.0 ± 3.43 | 33.1 ± 3.31 | 35.6 ± 3.13 | 33.7 ± 4.24 |
The observed values of hematocrit at week 24 are presented.
| Percentage of Hematocrit | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Hematocrit: Week 24 | 31.5 ± 3.72 | 32.4 ± 2.78 | 32.2 ± 4.11 | 32.8 ± 3.58 |
The observed values of hemoglobin at week 12 are presented.
| g/dL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Hemoglobin: Week 12 | 10.51 ± 1.190 | 10.37 ± 0.928 | 10.56 ± 1.018 | 10.53 ± 1.360 |
The observed values of hemoglobin at week 24 are presented.
| g/dL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Hemoglobin: Week 24 | 9.68 ± 1.057 | 10.06 ± 1.031 | 9.47 ± 1.135 | 9.87 ± 1.215 |
The observed values of hypochromatic red cells at week 12 are presented.
| Percentage of Hypochromatic red cells | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Hypochromatic Red Cells Week 12 | 13.65 ± 15.015 | 12.09 ± 11.191 | 23.65 ± 22.214 | 11.99 ± 14.657 |
The observed values of hypochromatic red cells at week 24 are presented.
| Percentage of Hypochromatic red cells | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Hypochromatic Red Cells: Week 24 | 11.88 ± 10.819 | 11.60 ± 11.895 | 32.02 ± 25.224 | 15.44 ± 13.415 |
The observed values of leukocytes at week 12 are presented.
| 10^3 cells/uL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Leukocytes: Week 12 | 5.23 ± 1.718 | 5.84 ± 1.837 | 4.68 ± 1.069 | 5.25 ± 3.004 |
The observed values of leukocytes at week 24 are presented.
| 10^3 cells/uL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Leukocytes: Week 24 | 5.52 ± 2.197 | 6.06 ± 1.689 | 5.52 ± 1.168 | 6.13 ± 3.414 |
The observed values of lymphocytes at week 12 are presented.
| 10^3 cells/uL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Lymphocytes: Week 12 | 1.10 ± 0.306 | 1.45 ± 0.678 | 1.11 ± 0.250 | 1.18 ± 0.388 |
The observed values of lymphocytes at week 24 are presented.
| 10^3 cells/uL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Lymphocytes: Week 24 | 1.10 ± 0.452 | 1.26 ± 0.496 | 1.08 ± 0.267 | 1.23 ± 0.523 |
Lymphocytes to leukocytes ratio at week 12 is presented.
| Ratio of lymphocytes to leukocytes | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Lymphocytes to Leukocytes Ratio: Week 12 | 22.86 ± 9.139 | 25.09 ± 9.611 | 24.15 ± 5.774 | 24.81 ± 7.341 |
Lymphocytes to leukocytes ratio at week 24 is presented.
| Ratio of lymphocytes to leukocytes | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Lymphocytes to Leukocytes Ratio at Week 24 | 21.47 ± 11.350 | 21.24 ± 7.195 | 20.63 ± 6.997 | 21.71 ± 7.633 |
The observed values of monocytes at week 12 are presented.
| 10^3 cells/uL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Monocytes: Week 12 | 0.26 ± 0.151 | 0.29 ± 0.171 | 0.25 ± 0.102 | 0.31 ± 0.119 |
The observed values of monocytes at week 24 are presented.
| 10^3 cells/uL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Monocytes: Week 24 | 0.40 ± 0.184 | 0.39 ± 0.200 | 0.31 ± 0.138 | 0.30 ± 0.067 |
Monocytes to leukocytes ratio at week 12 is presented.
| Ratio of monocytes to leukocytes | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Monocytes to Leukocytes Ratio: Week 12 | 5.61 ± 2.871 | 5.42 ± 2.649 | 5.15 ± 1.652 | 6.21 ± 2.230 |
Monocytes to leukocytes ratio at week 24 is presented.
| Ratio of monocytes to leukocytes | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Monocytes to Leukocytes Ratio: Week 24 | 7.04 ± 2.369 | 6.29 ± 2.281 | 5.49 ± 1.770 | 5.77 ± 2.396 |
The observed values of neutrophils at week 12 are presented.
| 10^3 cells/uL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Neutrophils: Week 12 | 3.68 ± 1.611 | 3.70 ± 1.455 | 3.09 ± 0.921 | 3.09 ± 1.354 |
The observed values of neutrophils at week 24 are presented.
| 10^3 cells/uL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Neutrophils: Week 24 | 3.82 ± 1.795 | 4.08 ± 1.252 | 3.71 ± 1.047 | 4.25 ± 2.507 |
Neutrophils to leukocytes ratio at week 12 is presented.
| Ratio of neutrophils to leukocytes | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Neutrophils to Leukocytes Ratio: Week 12 | 67.29 ± 11.707 | 62.41 ± 10.148 | 65.61 ± 7.447 | 60.79 ± 9.656 |
Neutrophils to leukocytes ratio at week 24 is presented.
| Ratio of neutrophils to leukocytes | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Neutrophils to Leukocytes Ratio: Week 24 | 67.37 ± 13.396 | 67.21 ± 8.771 | 67.31 ± 8.293 | 67.94 ± 8.750 |
The observed values of platelets at week 12 are presented.
| 10^3 cells/uL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Platelets: Week 12 | 169.8 ± 68.37 | 168.3 ± 38.62 | 129.4 ± 42.26 | 143.8 ± 48.68 |
The observed values of platelets at week 24 are presented.
| 10^3 cells/uL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Platelets: Week 24 | 180.2 ± 62.44 | 203.1 ± 57.78 | 151.6 ± 41.75 | 160.1 ± 55.67 |
Reticulocytes to erythrocytes ratio at week 12 is presented.
| Ratio of reticulocytes to erythrocytes | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Reticulocytes to Erythrocytes Ratio: Week 12 | 1.92 ± 0.852 | 1.68 ± 0.757 | 2.14 ± 1.203 | 2.32 ± 1.537 |
Reticulocytes to erythrocytes ratio at week 24 is presented.
| Ratio of reticulocytes to erythrocytes | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Reticulocytes to Erythrocytes Ratio: Week 24 | 1.95 ± 0.872 | 1.96 ± 0.669 | 1.84 ± 0.612 | 2.24 ± 0.935 |
The observed values of alanine aminotransferase at week 12 are presented.
| units per liter (U/L) | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Alanine Aminotransferase: Week 12 | 12.1 ± 6.61 | 18.6 ± 13.85 | 19.9 ± 10.89 | 19.0 ± 9.43 |
The observed values of alanine aminotransferase at week 24 are presented.
| U/L | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Alanine Aminotransferase: Week 24 | 8.7 ± 4.67 | 11.9 ± 4.78 | 15.3 ± 6.81 | 15.4 ± 6.35 |
The observed values of albumin at week 12 are presented.
| g/dL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Albumin: Week 12 | 3.96 ± 0.382 | 3.90 ± 0.210 | 3.97 ± 0.304 | 3.98 ± 0.273 |
The observed values of albumin at week 24 are presented.
| g/dL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Albumin: Week 24 | 3.75 ± 0.432 | 3.83 ± 0.305 | 3.77 ± 0.347 | 3.84 ± 0.456 |
The observed values of alkaline phosphatase at week 12 are presented.
| U/L | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Alkaline Phosphatase: Week 12 | 103.0 ± 56.43 | 125.4 ± 87.32 | 107.5 ± 57.54 | 106.2 ± 44.69 |
The observed values of alkaline phosphatase at week 24 are presented.
| U/L | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Alkaline Phosphatase: Week 24 | 99.8 ± 51.17 | 140.6 ± 119.26 | 121.2 ± 55.26 | 95.2 ± 53.01 |
The observed values of aspartate aminotransferase at week 12 are presented.
| U/L | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Aspartate Aminotransferase: Week 12 | 15.5 ± 5.89 | 18.1 ± 11.57 | 20.5 ± 10.85 | 15.7 ± 4.61 |
The observed values of aspartate aminotransferase at week 24 are presented.
| U/L | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Aspartate Aminotransferase: Week 24 | 14.7 ± 5.57 | 14.3 ± 5.59 | 17.3 ± 7.75 | 14.7 ± 3.20 |
The observed values of bicarbonate at week 12 are presented.
| millimoles per liter (mmol/L) | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Bicarbonate: Week 12 | 23.5 ± 3.06 | 23.1 ± 3.03 | 22.7 ± 3.26 | 25.5 ± 3.50 |
The observed values of bicarbonate at week 24 are presented.
| mmol/L | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Bicarbonate: Week 24 | 23.3 ± 3.00 | 24.6 ± 2.83 | 22.4 ± 2.43 | 26.0 ± 3.28 |
The observed values of bilirubin at week 12 are presented.
| mg/dL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Bilirubin: Week 12 | 0.490 ± 0.186 | 0.450 ± 0.157 | 0.603 ± 0.234 | 0.553 ± 0.150 |
The observed values of bilirubin at week 24 are presented.
| mg/dL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Bilirubin: Week 24 | 0.450 ± 0.169 | 0.430 ± 0.142 | 0.565 ± 0.184 | 0.520 ± 0.125 |
The observed values of calcium at week 12 are presented.
| mg/dL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Calcium: Week 12 | 8.89 ± 0.883 | 8.54 ± 0.737 | 8.90 ± 0.777 | 8.39 ± 0.727 |
The observed values of calcium at week 24 are presented.
| mg/dL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Calcium: Week 24 | 8.73 ± 0.740 | 8.95 ± 0.734 | 8.76 ± 0.653 | 8.82 ± 1.011 |
The observed values of chloride at week 12 are presented.
| mmol/L | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Chloride: Week 12 | 97.0 ± 3.69 | 98.6 ± 5.34 | 98.0 ± 4.87 | 98.5 ± 2.47 |
The observed values of chloride at week 24 are presented.
| mmol/L | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Chloride: Week 24 | 98.5 ± 3.67 | 97.7 ± 4.76 | 98.7 ± 3.15 | 97.6 ± 3.73 |
The observed values of cholesterol at week 12 are presented.
| mg/dL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Cholesterol: Week 12 | 140.4 ± 41.24 | 140.3 ± 40.51 | 145.9 ± 41.38 | 146.0 ± 43.54 |
The observed values of cholesterol at week 24 are presented.
| mg/dL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Cholesterol: Week 24 | 130.5 ± 40.19 | 148.3 ± 38.74 | 131.2 ± 36.17 | 158.0 ± 44.04 |
The observed values of creatinine at week 12 are presented.
| mg/dL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Creatinine: Week 12 | 9.458 ± 2.739 | 9.616 ± 2.642 | 9.227 ± 2.526 | 10.115 ± 3.391 |
The observed values of creatinine at week 24 are presented.
| mg/dL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Creatinine: Week 24 | 9.086 ± 2.260 | 9.173 ± 2.541 | 9.027 ± 2.216 | 9.703 ± 3.714 |
The observed values of direct bilirubin at week 12 are presented.
| mg/dL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Direct Bilirubin: Week 12 | 0.101 ± 0.071 | 0.098 ± 0.066 | 0.123 ± 0.049 | 0.118 ± 0.059 |
The observed values of direct bilirubin at week 24 are presented.
| mg/dL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Direct Bilirubin: Week 24 | 0.105 ± 0.081 | 0.081 ± 0.046 | 0.124 ± 0.053 | 0.102 ± 0.042 |
The observed values of glucose at week 12 are presented.
| mg/dL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Glucose: Week 12 | 123.1 ± 52.29 | 128.5 ± 66.17 | 119.6 ± 73.49 | 101.2 ± 19.86 |
The observed values of glucose at week 24 are presented.
| mg/dL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Glucose: Week 24 | 129.5 ± 54.83 | 129.9 ± 64.12 | 142.4 ± 168.55 | 104.2 ± 22.97 |
The observed values of HDL cholesterol at week 12 are presented.
| mg/dL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| High-density Lipoprotein (HDL) Cholesterol: Week 12 | 51.6 ± 16.47 | 50.1 ± 18.05 | 54.2 ± 17.17 | 52.5 ± 15.14 |
The observed values of HDL cholesterol at week 24 are presented.
| mg/dL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| HDL Cholesterol: Week 24 | 50.5 ± 17.33 | 45.4 ± 16.02 | 48.8 ± 16.29 | 46.8 ± 22.49 |
The observed values of hepcidin-25 at week 12 are presented.
| nanogram/milliliter (ng/mL) | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Hepcidin-25: Week 12 | 310.67 ± 163.569 | 344.99 ± 154.189 | 288.72 ± 210.049 | 233.89 ± 114.748 |
The observed values of hepcidin-25 at week 24 are presented.
| ng/mL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Hepcidin-25: Week 24 | 347.55 ± 167.752 | 328.35 ± 159.543 | 302.72 ± 131.966 | 262.18 ± 118.461 |
The observed values of LDL cholesterol at week 12 are presented.
| mg/dL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Low-density Lipoproteins (LDL) Cholesterol: Week 12 | 67.2 ± 29.62 | 61.4 ± 31.40 | 63.8 ± 32.69 | 68.1 ± 39.58 |
The observed values of LDL cholesterol at week 24 are presented.
| mg/dL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| LDL Cholesterol: Week 24 | 60.9 ± 32.59 | 69.4 ± 30.44 | 54.7 ± 27.73 | 82.7 ± 35.43 |
The observed values of lipoprotein-a at week 12 are presented.
| Nanomoles per litre (nmol/L) | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Lipoprotein-a: Week 12 | 35.2 ± 38.88 | 86.3 ± 83.29 | 68.9 ± 50.11 | 53.1 ± 41.54 |
The observed values of lipoprotein-a at week 24 are presented.
| nmol/L | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Lipoprotein-a: Week 24 | 39.3 ± 37.60 | 96.6 ± 92.52 | 89.5 ± 61.25 | 61.9 ± 52.28 |
The observed values of phosphate at week 12 are presented.
| mg/dL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Phosphate: Week 12 | 5.06 ± 1.425 | 5.67 ± 1.905 | 6.51 ± 1.364 | 5.43 ± 1.416 |
The observed values of phosphate at week 24 are presented.
| mg/dL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Phosphate: Week 24 | 5.55 ± 1.841 | 4.57 ± 1.399 | 5.15 ± 0.724 | 5.64 ± 1.459 |
The observed values of potassium at week 12 are presented.
| mmol/L | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Potassium: Week 12 | 5.13 ± 1.094 | 5.06 ± 0.754 | 5.03 ± 0.662 | 4.69 ± 0.647 |
The observed values of potassium at week 24 are presented.
| mmol/L | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Potassium: Week 24 | 4.96 ± 0.628 | 4.97 ± 0.581 | 4.71 ± 0.466 | 4.75 ± 0.762 |
The observed values of sodium at week 12 are presented.
| mmol/L | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Sodium: Week 12 | 135.8 ± 2.80 | 137.1 ± 4.55 | 137.4 ± 4.03 | 138.6 ± 3.64 |
The observed values of sodium at week 24 are presented.
| mmol/L | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Sodium: Week 24 | 136.7 ± 3.04 | 136.2 ± 4.90 | 137.8 ± 4.24 | 137.2 ± 4.06 |
The observed values of triglyceride at week 12 are presented.
| mg/dL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Triglycerides: Week 12 | 107.9 ± 50.59 | 140.8 ± 131.19 | 139.5 ± 85.00 | 126.7 ± 89.04 |
The observed values of triglycerides at week 24 are presented.
| mg/dL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Triglycerides: Week 24 | 95.4 ± 53.98 | 166.9 ± 120.39 | 146.6 ± 147.52 | 142.9 ± 95.94 |
The observed values of urea nitrogen at week 12 are presented.
| mg/dL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Urea Nitrogen: Week 12 | 61.7 ± 26.03 | 61.1 ± 17.40 | 53.3 ± 12.38 | 62.1 ± 21.06 |
The observed values of urea nitrogen at week 24 are presented.
| mg/dL | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Urea Nitrogen: Week 24 | 66.2 ± 30.04 | 59.9 ± 16.97 | 51.1 ± 13.67 | 59.6 ± 15.11 |
Pre-dialysis BMI values at week 12 are presented.
| kilogram per meter^2 (kg/m^2) | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Pre-dialysis Body Mass Index (BMI): Week 12 | 28.952 ± 5.774 | 29.668 ± 8.674 | 32.150 ± 9.365 | 32.574 ± 8.240 |
Pre-infusion BMI values at week 11 are presented.
| Kg/m^2 | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Pre-infusion BMI: Week 11 | 29.337 ± 6.800 | 29.399 ± 8.267 | 31.290 ± 8.341 | 34.163 ± 7.950 |
Pre-dialysis diastolic blood pressure values at week 12 are presented.
| Millimetre of mercury (mm Hg) | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Pre-dialysis Diastolic Blood Pressure: Week 12 | 84.8 ± 21.14 | 70.4 ± 11.70 | 84.2 ± 10.23 | 76.3 ± 16.29 |
Pre-dialysis diastolic blood pressure values at week 24 are presented.
| mm Hg | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Pre-dialysis Diastolic Blood Pressure: Week 24 | 76.9 ± 13.59 | 77.8 ± 13.23 | 74.0 ± 14.53 | 78.8 ± 13.74 |
Pre-infusion diastolic blood pressure values at week 11 are presented.
| mm Hg | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Pre-infusion Diastolic Blood Pressure: Week 11 | 82.3 ± 19.68 | 66.6 ± 10.03 | 75.8 ± 11.80 | 78.7 ± 10.71 |
Pre-dialysis heart rate values at week 12 are presented.
| beats/min | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Pre-dialysis Heart Rate: Week 12 | 69.3 ± 7.50 | 71.1 ± 12.20 | 70.8 ± 8.03 | 76.9 ± 13.37 |
Pre-dialysis heart rate values at week 24 are presented.
| beats/min | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Pre-dialysis Heart Rate: Week 24 | 71.8 ± 12.02 | 78.0 ± 11.90 | 72.6 ± 10.03 | 78.9 ± 17.72 |
Pre-infusion heart rate values at week 11 are presented.
| beats/min | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Pre-infusion Heart Rate: Week 11 | 67.1 ± 6.11 | 70.1 ± 9.44 | 65.7 ± 8.88 | 72.8 ± 9.80 |
Pre-dialysis respiration rate values at week 12 are presented.
| breaths per minute (breaths/min) | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Pre-dialysis Respiration Rate: Week 12 | 17.8 ± 1.27 | 17.9 ± 1.29 | 17.9 ± 1.53 | 18.1 ± 1.31 |
Pre-dialysis respiration rate values at week 24 are presented.
| breaths/min | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Pre-dialysis Respiration Rate: Week 24 | 16.6 ± 2.69 | 18.1 ± 1.09 | 18.3 ± 1.60 | 18.4 ± 1.08 |
Pre-infusion respiration rate values at week 11 are presented.
| breaths/min | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Pre-infusion Respiration Rate: Week 11 | 18.1 ± 1.22 | 17.8 ± 1.24 | 18.1 ± 1.39 | 18.3 ± 1.23 |
Pre-dialysis values of systolic blood pressure at week 12 are presented.
| mm Hg | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Pre-dialysis Systolic Blood Pressure: Week 12 | 164.4 ± 33.13 | 143.8 ± 21.04 | 164.3 ± 25.17 | 151.4 ± 26.83 |
Pre-dialysis values of systolic blood pressure at week 24 are presented.
| mm Hg | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Pre-dialysis Systolic Blood Pressure: Week 24 | 149.4 ± 30.43 | 146.7 ± 19.14 | 157.6 ± 27.45 | 155.8 ± 22.93 |
Pre-infusion systolic blood pressure values at week 11 are presented.
| mm Hg | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Pre-infusion Systolic Blood Pressure: Week 11 | 161.2 ± 25.78 | 138.7 ± 27.32 | 144.0 ± 28.30 | 152.1 ± 28.18 |
Pre-dialysis weight values at week 12 are presented.
| Kilogram (Kg) | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Pre-dialysis Weight: Week 12 | 84.583 ± 18.464 | 82.162 ± 28.830 | 92.120 ± 25.720 | 96.213 ± 29.206 |
Pre-infusion weight values at week 11 are presented.
| Kg | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Pre-infusion Weight: Week 11 | 86.356 ± 21.881 | 83.433 ± 31.580 | 92.043 ± 26.401 | 91.217 ± 15.121 |
Pre-dialysis temperature values at week 12 are presented.
| Celsius (C) | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Pre-dialysis Temperature: Week 12 | 36.259 ± 0.572 | 36.435 ± 0.304 | 36.436 ± 0.314 | 36.490 ± 0.157 |
Pre-dialysis temperature values at week 24 are presented.
| C | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Pre-dialysis Temperature: Week 24 | 36.328 ± 0.384 | 36.440 ± 0.315 | 36.168 ± 0.370 | 36.361 ± 0.251 |
Pre-infusion temperature values at week 11 are presented.
| C | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Pre-infusion Temperature: Week 11 | 36.182 ± 0.692 | 36.377 ± 0.259 | 36.187 ± 0.494 | 36.375 ± 0.193 |
Area under the serum concentration time curve from time 0 to infinity (AUC 0-α) of COR-001 is presented.
| nanogram*day/milliliter (ng*day/mL) | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|
| Area Under the Serum Concentration Time Curve From Time 0 to Infinity (AUC 0-α) of COR-001 | 11962 ± 4731 | 40911 ± 23629 | 118177 ± 60393 |
Elimination half-life in the initial phase (t 1/2,α) is presented from week 0 to week 35.
| Days | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|
| Elimination Half-life in the Initial Phase (t 1/2,α) | 2.55 ± 0.94 | 1.98 ± 0.87 | 1.90 ± 0.70 |
Elimination half-life in the terminal phase(t 1/2, z) is presented from week 0 to week 35.
| Days | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|
| Elimination Half-life in the Terminal Phase (t 1/2, z) | 51.44 ± 21.55 | 38.22 ± 14.21 | 40.93 ± 13.43 |
Maximum serum concentration (Cmax) of COR-001 from week 0 to week 35 is presented.
| ng/mL | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|
| Maximum Serum Concentration (Cmax) | 378 ± 93 | 1368 ± 359 | 3584 ± 1349 |
Presence of ADA was a covariate for pharmacokinetics (PK) affecting V1 (volume of distribution for the central compartment). Impact of ADAs on V1 from baseline to week 35 is presented. In the below table, result presented is the bootstrap parameter estimate of the effect of ADA on V1 for a PK model that includes data for all arms combined.
| Milliliter (mL) | COR-001 |
|---|---|
| Impact of ADAs on Pharmacokinetics | 0.361 (0.0548 to 0.658) |
Collected over Weeks 0-24. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/12 (0%) | 3/12 (25%) | 7/12 (58.3%) |
| COR-001 2 mg | 0/16 (0%) | 4/16 (25%) | 11/16 (68.8%) |
| COR-001 6 mg | 2/16 (12.5%) | 7/16 (43.8%) | 15/16 (93.8%) |
| COR-001 20 mg | 2/17 (11.8%) | 6/17 (35.3%) | 10/17 (58.8%) |
| Event | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| Cardiac failure congestiveCardiac disorders | 0/12 | 0/16 | 4/16 | 0/17 |
| Hypertensive emergencyVascular disorders | 2/12 | 0/16 | 1/16 | 0/17 |
| Fluid overloadMetabolism and nutrition disorders | 0/12 | 0/16 | 2/16 | 0/17 |
| Arteriovenous fistula site complicationInjury, poisoning and procedural complications | 1/12 | 0/16 | 0/16 | 0/17 |
| Arteriovenous fistula site infectionInfections and infestations | 1/12 | 0/16 | 0/16 | 0/17 |
| EncephalopathyNervous system disorders | 1/12 | 0/16 | 0/16 | 0/17 |
| HypertensionVascular disorders | 1/12 | 0/16 | 0/16 | 0/17 |
| Osteomyelitis acuteInfections and infestations | 1/12 | 0/16 | 0/16 | 0/17 |
| AnaemiaBlood and lymphatic system disorders | 0/12 | 0/16 | 1/16 | 0/17 |
| Appendicitis perforatedInfections and infestations | 0/12 | 1/16 | 0/16 | 0/17 |
| Event | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg |
|---|---|---|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/12 | 0/16 | 4/16 | 1/17 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/12 | 2/16 | 3/16 | 0/17 |
| VomitingGastrointestinal disorders | 1/12 | 3/16 | 1/16 | 0/17 |
| HyperparathyroidismEndocrine disorders | 2/12 | 0/16 | 0/16 | 0/17 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 2/12 | 1/16 | 1/16 | 1/17 |
| Diabetes mellitus inadequate controlMetabolism and nutrition disorders | 0/12 | 0/16 | 2/16 | 0/17 |
| HyperkalaemiaMetabolism and nutrition disorders | 0/12 | 2/16 | 2/16 | 0/17 |
| HypertensionVascular disorders | 0/12 | 0/16 | 2/16 | 1/17 |
| HyponatraemiaMetabolism and nutrition disorders | 0/12 | 0/16 | 2/16 | 1/17 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/12 | 0/16 | 0/16 | 2/17 |
Intent-to-Treat (ITT) population included all randomized participants.
| Age, Continuous(Years) | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg | Total |
|---|---|---|---|---|---|
| Mean | 62.8 ± 10.23 | 61.4 ± 12.95 | 63.8 ± 10.98 | 57.9 ± 10.56 | 61.3 ± 11.24 |
| Sex: Female, Male(Participants) | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg | Total |
|---|---|---|---|---|---|
| Female | 3 | 9 | 8 | 9 | 29 |
| Male | 9 | 7 | 8 | 8 | 32 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 6 | 7 | 3 | 4 | 20 |
| Not Hispanic or Latino | 6 | 9 | 13 | 13 | 41 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | COR-001 2 mg | COR-001 6 mg | COR-001 20 mg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 2 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 5 | 5 | 10 | 11 | 31 |
| White | 7 | 10 | 4 | 5 | 26 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
Ran from Sep 2016 to primary completion in Dec 2018, 26 months.
Results were first posted in Jul 2021, 2 years 7 months after primary completion. A results delay was requested in Jan 2021.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ziltivekimab